68 results about "Receptor expression" patented technology

The invention discloses a two-dimensional bionic nanostructure assembled based on receptor-ligand acting force and a preparation method of the two-dimensional bionic nanostructure. The core characteristic of the two-dimensional bionic nanostructure is that the ultrafine particles modified by ligand molecules are anchored on the surface of a cell membrane fragment with a corresponding receptor expressed on the surface through a receptor-ligand effect, so that uniform compounding of the ultrafine particles and the cell membrane is realized; the bottlenecks of low compounding efficiency, functional site masking and the like caused by high surface curvature of small-size particles in the traditional cell membrane complete wrapping technology are broken through. According to the preparation method disclosed by the invention, the binding force between the cell membrane and the ultramicro particles is stronger, the off-target phenomenon of the ultramicro particles in the in-vivo circulation process can be avoided, the response release of the ultramicro particles under the competition effect in a lesion region expressed by a high-abundance receptor can be realized, and the preparation method has a good application prospect in the aspect of precise drug delivery. Meanwhile, the in-vivo circulation time of the ultrafine particles is prolonged by membrane loading, the biocompatibility of the ultrafine particles is improved, and the effectiveness and low toxicity of a drug delivery system are ensured.

The invention discloses an imitated intercorial nano preparation for treating acute respiratory distress syndrome, and belongs to the technical field of biological medicine. The internalized nano preparation comprises an active component, a liposome phospholipid bilayer and a target head, wherein the active component consists of an ROS (reactive oxygen species) removing drug and an anti-inflammatory drug. According to the invention, efficient and accurate targeting of the nano-preparation is realized by innovatively applying an imitated interment effect, an apoptotic cell marker is modified on the surface of the liposome, and an'eat me 'signal is released to simulate a natural biological process that macrophages clear apoptotic cells to be recognized and swallowed by alveolar macrophages, so that efficient and specific targeting is realized, and the targeting effect of the nano-preparation is improved. Meanwhile, up-regulation of PS receptor expression of macrophages at the inflammation part further enhances the targeting effect, and a new way is provided for efficient delivery of acute respiratory distress syndrome medicine preparations and remodeling of pathological microenvironment.

The present invention inter alia relates to a chimeric transmembrane receptor comprising a polypeptide, wherein the polypeptide comprises at least one T cell immunoreceptor with Ig and ITIM domains (TIGIT) polypeptide region comprising a TIGIT extracellular ligand binding domain; further wherein the polypeptide comprises at least one non-TIGIT polypeptide region, wherein the at least one non-TIGIT polypeptide region comprises a transmembrane polypeptide region of CD2, CD40, HVEM, or CD30, and wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2, CD40, HVEM, or CD30, or wherein the transmembrane domain is from TIGIT and further wherein the at least one non-TIGIT polypeptide region comprises at least one costimulatory cytoplasmic polypeptide domain, region or motif of CD2 or CD28. The invention also relates to corresponding nucleic acids, vectors and T-cells comprising or expressing the chimeric receptors, to a pharmaceutical composition comprising the T-cells, and to methods for preparing a T-cell for immunotherapy and for treating a disease, respectively, wherein the chimeric transmembrane receptor is used.

The present invention relates to novel cell lines for the expression of the human LHCG receptor and for the expression of the human LHCG receptor and a luciferase reporter gene. Methods for producing such cell lines are also described. The cell lines of the present invention, which express the LHCG receptor and a luciferase reporter gene, can be used in methods for determining the presence and biological activity of r-hLH and r-hCG samples.

The invention provides a method for regulating and controlling proliferation and movement of human peripheral blood T cells by Amuc1100 protein. The method relates to the technologies of separation, activation and culture of human peripheral blood T cells, CCK-8 cell proliferation detection, Transwell cell chemotactic detection, flow cytometry receptor expression body detection and the like. The application of the Amuc1100 protein to treat T cells proves that the protein can significantly down-regulate the expression of CD25 and CXCR4 of the T cells and inhibit T cell proliferation and CXCL12 induced T cell chemotactic movement respectively. The method and research means for in-vitro regulation of T cell proliferation and chemotactic movement can be applied to targeted regulation of T cells and directional migration of intestinal tracts of the T cells, and are used for maintaining the steady state of the intestinal tracts, relieving intestinal inflammations and screening drugs to treat diseases related to the intestinal inflammations.

The present invention inter alia relates to a T-cell expressing a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95-derived polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 wildtype receptor, wherein said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95-derived co- stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, OX40, and / or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and / or an IL6-receptor family protein; wherein the T-cell further expresses an engineered T-cell receptor. The present invention also relates to a vector comprising nucleic acids encoding for the CD 95 receptor and the engineered T-cell receptor, as well as to a kit for preparing the T-cells of the present invention, and a pharmaceutical composition comprising the T-cells. The invention also relates to a method for preparing a T-cell for immunotherapy, and to a method for treating a patient having a disease comprising administering the pharmaceutical composition.

This invention discloses a composition and method comprising bis(demethoxycurcumin) enriched in at least 20% w / w for inhibiting receptor for advanced glycation end products (RAGE) expression in subjects with chronic inflammatory conditions. The composition further comprises β-amyrin palmitate (BAP). This invention also discloses the use of the above composition in controlling chronic inflammatory conditions in subjects.

The present invention relates to NK cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof. In the present invention, it was found that the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent when, among the cell surface proteins of PBMCs for producing CAR-NK cells (UCI-101), CD16 is expressed at 70% or less, natural killer group 2D (NKG2D) is expressed at less than 10%, CD57 is expressed at 30% or less, low-density lipoprotein receptor (LDLR) is expressed at 0.1% or more, and natural cytotoxicity triggering receptor 3 (NKp30) is expressed at less than 10%. In addition, optimal conditions for inducing NK cell differentiation and optimal conditions for transduction, under which the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent, were established, and CAR-NK cells produced by the method according to the present invention were found to exhibit an excellent antitumor effect in an animal model, and thus can be effectively used as a composition for preventing or treating diseases related to CD22 (or CD19) expression or diseases related to B cells.

The application discloses a composition for inducing T cell reprogramming into NK-like cells and application thereof. The composition comprises a DNA methyltransferase inhibitor, a histone deacetylase inhibitor and a vitamin C phosphate derivative; the molar ratio of the DNA methyltransferase inhibitor and the vitamin C phosphate derivative is 1: (40-2500); and the final concentration of the histone deacetylase inhibitor is 0.05-2 muM. The vitamin C phosphate derivative is used to replace common vitamin C, and the defects of common vitamin C, such as weak reprogramming promotion effect in a platelet lysate system, limited cell proliferation and low receptor expression, are overcome, so that the composition is more suitable for a clinical serum-free large-scale preparation scene.

The invention discloses a preparation method of brassinolide derived carbon quantum dots and application of the brassinolide derived carbon quantum dots in plant hormone receptor detection. According to the method, BRs is used as a precursor, CQDs with a BRs semi-reserved structure are prepared through co-carbonization with citric acid, and the nano material with the particle size of 3.1 + / -0.5 nm and the surface rich in hydroxyl / keto is obtained after dialysis and purification. When the CQDs are combined with the BRs receptors, the fluorescence intensity of the CQDs is linearly enhanced along with the concentration of the receptors, the nano sensor constructed based on the CQDs can realize rapid quantitative detection of the BRs receptors in rice leaves, the linear range is 0.01-4.0 mg / mL, the detection limit is as low as 0.003 mg / mL, and the sensitivity is improved by 10 times compared with that of ELISA (Enzyme-Linked Immunosorbent Assay). By detecting the receptor expression quantity of a wild type and BRs receptor overexpression strain in a germination period, a heading period and a mature period, it is verified that the result of the strain is highly consistent with that of Western Blot, and the detection time is shortened to 30 minutes. The method does not need targeted modification, has the advantages of high specificity, interference resistance and low cost, and provides an efficient detection tool for rice molecular breeding and stress resistance regulation.

The present invention discloses the use of a reagent for measuring the expression level of discoidin domain receptor 2 (DDR2) in the manufacture of a kit for diagnosing a neurodegenerative disease in a subject, wherein a higher level of DDR2 in a sample derived from the subject than that of a control not affected by the disease indicates that the subject is affected by the neurodegenerative disease. The present invention also discloses a kit, method, and computer-readable medium for diagnosing neurodegenerative diseases. The present invention efficiently and accurately diagnoses neurodegenerative diseases by measuring DDR2.

To provide a novel composition capable of promoting expression of a pleiotrophin receptor.SOLUTION: An agent for enhancing pleiotrophin receptor expression comprising, as an active ingredient, one or two or more plant extracts of plants selected from the group consisting of Ruscus aculeatus, Olea europaea, and Plantago major.SELECTED DRAWING: Figure 2

The present application relates to the use of amphotericin B or its combination in the preparation of anti-tumor drugs. The present application first confirms that amphotericin B directly binds to Toll-like receptor 2 and activates the downstream signaling pathway as a Toll-like receptor 2 agonist, thereby enhancing the phagocytic ability of macrophages to tumor cells; it is first confirmed that amphotericin B combined with therapeutic antibodies can produce a synergistic anti-tumor effect, and the above synergistic effect is mainly due to the regulatory effect of amphotericin B on macrophage function, including enhancing Fc gamma receptor expression and polarizing macrophages to M1 direction, which provides a solid foundation for the clinical transformation of amphotericin B and is expected to provide new treatment options for cancer patients.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed, herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.

To provide an inhibitor of expression of a receptor for adherence of pneumonia-causing bacteria.SOLUTION: An inhibitor of expression of a receptor for adherence of pneumonia-causing bacteria comprises at least one selected from the group consisting of hesperidin, cinnamaldehyde, citric acid hydrate, L-glutamic acid hydrochloride, and tartaric acid.SELECTED DRAWING: None

The present invention relates to methods for identifying cancer, responders, predicting response and stratifying patients with respect to a combination therapy comprising the administration of a P2X4 receptor inhibitor and a cell death inducing chemotherapy. The methods according to the present invention are based on the detection of P2X4 receptor protein expression in cells of a patient-derived cancer sample, e.g. cells or organoids, to identify cancer, responders, predict responders and stratify patients, wherein an increase in protein expression identifies cancer, responders and predicts responders when applying the combination therapy and also allows to stratify the patients accordingly.

The invention discloses a CCK2R ligand compound, a radiolabeled compound and application thereof, and relates to the technical field of biological medicine. Wherein the structural general formula of the CCK2R ligand compound is shown in the specification; wherein R is a chelating group, and n is an integer from 3 to 5. The CCK2R ligand compound has good CCK2R binding capacity, compared with a tracer agent or a therapeutic agent in the prior art, the radiolabeled compound composed of the CCK2R ligand compound and radionuclide has equivalent or even higher uptake value on tumors expressed by cholecystokinin II type receptors, the in-vivo inhibition effect is remarkable, and the CCK2R ligand compound can be used for preparing the radiolabeled compound for treating the tumors expressed by the cholecystokinin II type receptors. And a new strategy is provided for diagnosis and treatment of tumors with cholecystokinin II type receptor expression.

The present invention discloses a chimeric switch receptor for macrophages and its application, which belongs to the field of biomedicine technology. The chimeric switch receptor for macrophages provided by the present invention includes: an extracellular region, the extracellular region includes the extracellular domain of IL-2α, IL-2β or IL-2γ receptor; a transmembrane region, the transmembrane region includes the transmembrane domain of CD8 or CD28 molecule; an intracellular region, the intracellular region includes the intracellular domain of CD3ζ, TLR4, CD40 or Dectin1 molecule. The chimeric switch receptor of the present invention is expressed on the surface of tumor-associated macrophages, which can induce M2 macrophages to transform towards M1 phenotype after binding of exogenous IL-2 to the chimeric switch receptor on the cell surface, thereby fully exerting the phagocytic and killing effect on tumor cells.

The invention belongs to the technical field of biology, and discloses an influenza B virus sensitizing cell strain as well as a construction method and application thereof. The influenza B virus sensitizing cell strain STX-BB2 can be used for stably expressing influenza virus receptor ST6GAL1 protein in a human source and controllably inducing and expressing influenza B virus PB2 protein by using doxycycline; the preservation number of the cell strain STX-BB2 is GDMCC (China General Microbiological Culture Collection Center) NO: 67100; the cell strain can enhance the expression ability of a host receptor and the virus replication key gene level at the same time; the infection efficiency and the replication titer of the influenza B virus in MDCK cells can be improved; the method can be widely applied to influenza B virus separation, mechanism research, vaccine seed virus amplification and drug screening model construction.

The present invention, as described herein, relates to a novel cell line for expressing the human FSH receptor together with a luciferase reporter gene. Methods for preparing such cell lines are also described. The cell lines of the present invention expressing the FSH receptor and luciferase reporter gene can be used in methods for determining the presence and biological activity of r-FSH samples.

Provided herein are oligonucleotides for inhibiting the expression of Activin receptor 2B (ACVR2B) and methods of using the oligonucleotides for reducing ACVR2B expression in a subject.

The present invention relates to a humanised sequence binding the receptor tyrosine kinase ErbB3 / HER3 for the generation of anti-ErbB3 / HER3 antibodies in different formats, such as, for example, immunoglobulins, bispecific antibodies, in particular bispecific T-cell engagers, or antibody-drug conjugates (ADCs) or fusion immunoproteins, for the treatment of solid tumours depending on the expression of the ErbB3 receptor.

This invention discloses a radioactive triazolidinedimethylpyrimidine derivative, its preparation method, and its applications. The derivative has the structure shown in Formula I. Compared with the prior art, this invention provides a class of high-affinity adenosine A derivatives. 2A Radioactive triazolidinedimethyl derivatives of the receptor. This class of compounds belongs to the diagnostic category A. 2A Novel compounds for receptor-related diseases, and derivatives thereof prepared to target A 2A Imaging of the receptor, compared with previously reported targeting of A 2A Compared to receptor-specific radiopharmaceuticals, the radioactive compounds of this invention can rapidly reach equilibrium in the brain, thereby facilitating A. 2A Rapid quantification and qualitative analysis of receptors. The compounds of this invention can be applied not only to A... 2A The diagnosis of receptor-related brain diseases can also be applied to A 2A Diagnosis and efficacy evaluation of tumors with high receptor expression.

This invention discloses the application of the FAM26F gene in the diagnosis and treatment of depression, belonging to the interdisciplinary field of molecular biology and neuropsychiatry. This invention reveals for the first time that downregulation of the FAM26F gene expression disrupts glutamate homeostasis by affecting the expression of glutamate transporters and receptors, thereby leading to depressive-like behaviors. Based on this, this invention provides two core applications: first, the application of the FAM26F gene in the preparation of diagnostic products for depression, achieving objective diagnosis by detecting the expression level of this gene in samples such as peripheral blood; second, the application of the FAM26F gene in the preparation of therapeutic drugs for depression, wherein the drug uses a gene therapy vector that upregulates the expression of this gene as its active ingredient, and is administered via lateral ventricle injection or nasal nebulization, effectively reversing depressive-like behaviors in animal models. This invention provides a novel, precise diagnostic target and targeted treatment strategy for depression.

The present invention relates to compounds of Table 1, which are encompassed by Formula I and / or Formula II, Ill, IV, V, or VI, and pharmaceutically acceptable salts, solvates or compositions thereof. Compounds of Table 1 are PCSK9 interacting small molecules that modulate PCSK9 activity and significantly increase low density lipoprotein receptor expression and activity, lower total circulating cholesterol and are useful for treating and delaying the onset of diseases that are associated with elevated cholesterol.

The invention provides a culture medium for maintaining expression of key receptors of breast cancer organs and a preparation method of the culture medium. The culture medium comprises the following components: a basic culture medium, 1.25 to 2 mM of N-acetyl-L-cysteine, 1 * of N2, 1 * of B27, 1 * of Glutamax, 10 mM of HEPES, 1 [mu] M of SB202190, 5 to 10 mM of nicotinamide, 0.5 to 1 [mu] M of A83-01, 5 [mu] M of Y27632, 0.1 to 1 [mu] M of Verteporfin, 10 [mu] M of Sovesudil, 50 to 100 ng / mL of R-Spondin, 250 ng / mL of Noggin, 5 ng / mL of EGF, 5 ng / mL of Neuregulin 1, 200 ng / mL of The culture medium for maintaining the expression of the key receptor in the breast cancer organoid realizes stable maintenance of the expression of the key receptor in the breast cancer organoid, and provides a more accurate and reliable organoid model for research and treatment of breast cancer.

This invention provides a substituted tetrahydroquinoline derivative and its application, which is a class of compounds with AR antagonistic activity. These compounds competitively bind to androgens, blocking AR activation and inhibiting the AR signaling pathway. Experiments have confirmed that the synthesized compounds all possess excellent AR antagonistic activity, showing strong inhibitory activity in the human prostate cancer cell line LNCaP. Therefore, they can be used to prepare drugs for treating diseases with abnormal androgen receptor expression, such as tumors including but not limited to prostate cancer, metastatic prostate cancer, castration-resistant prostate cancer, breast cancer, and ovarian cancer. The general structural formula of the compounds is shown in formula (a):

This invention discloses a method for detecting the killing effect of multiple HLA-specific T cells, belonging to the field of biotechnology. This invention enables T2 cells to express various HLA-I molecular subtypes. After the receptor is expressed, antigen fragments loaded with various HLA-I molecules can be captured in the culture supernatant for in vitro evaluation of the killing effect of HLA-I-adapted antigen-specific T cells, thus expanding the application of T2 cells in in vitro killing effect evaluation. Simultaneously, it avoids the enormous workload and high cost of using the K562 cell line to construct a cell line for each HLA subtype-specific antigen fragment during the HLA subtype construction process.

The invention relates to the technical field of biotechnology and cell engineering, in particular to a large-scale culture method of central memory T cells (TCM). According to the method, the lymphocyte expressed by the high homing receptor is activated by adopting an alternating electric field, and the cell activity is improved by combining with a composite metabolism regulator. A two-photon excitation three-dimensional scaffold of a modified collagen peptide, ferroferric oxide and a quantum dot labeled organoid is utilized to simulate an in-vivo microenvironment to promote cell anchoring. And finally, through gene editing, engineering a cryopreservation system of saccharomyces cerevisiae and ultraviolet light activated autophagic peptide, so as to realize the enhancement of cell function stability and long-term memory characteristic. According to the invention, the limitation of traditional two-dimensional culture is broken through, and an efficient and controllable T cell preparation scheme is provided for tumor immunotherapy, autoimmune disease regulation and personalized cell therapy through systematic integration of physical field regulation, bionic scaffold design and genetic engineering means.

The invention provides a construction method and application of siRNA for inhibiting expression of a canine APN receptor, and belongs to the field of gene engineering. According to the method, siRNA is connected to a saRNA vector. The invention also provides a method for interfering the expression of the canine APN receptor and application of the method in inhibiting canine coronavirus infection. The siRNA is connected with the saRNA vector, expression of APN in mouse blood can be continuously inhibited, and the silencing time is prolonged to 150 days while the silencing effect of the APN in the mouse blood is maintained.